Captrust Financial Advisors Esperion Therapeutics, Inc. Transaction History

Captrust Financial Advisors

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.73 - $3.08 $7,336 - $30,954	10,050 New	10,050 $30,000
Q2 2023 Aug 14, 2023	BUY	$1.2 - $1.76 $12,122 - $17,779	10,102 New	10,102 $14,000
Q2 2022 Aug 16, 2022	BUY	$4.77 - $6.67 $10,150 - $14,193	2,128 Added 1156.52%	2,312 $15,000
Q1 2022 May 16, 2022	BUY	$3.34 - $5.56 $280 - $467	84 Added 84.0%	184 $1,000
Q4 2021 Feb 14, 2022	SELL	$4.81 - $11.92 $2,164 - $5,364	-450 Reduced 81.82%	100 $0
Q3 2021 Nov 16, 2021	BUY	$11.34 - $21.37 $4,331 - $8,163	382 Added 227.38%	550 $7,000
Q2 2021 Aug 16, 2021	BUY	$19.4 - $28.71 $174 - $258	9 Added 5.66%	168 $4,000
Q1 2021 May 17, 2021	SELL	$25.12 - $36.89 $7,309 - $10,734	-291 Reduced 64.67%	159 $4,000
Q3 2020 Nov 17, 2020	SELL	$31.18 - $52.71 $3,118 - $5,271	-100 Reduced 18.18%	450 $16,000
Q2 2020 Aug 14, 2020	BUY	$30.04 - $51.31 $16,522 - $28,220	550 New	550 $28,000

210

129M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $119M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.